Cytomegalovirus gastritis after rituximab treatment in a nonHodgkln's lymphoma patient

作     者：Ugur Unluturk Sercan Aksoy Ozlem Yonem Yusuf Bayraktar Gulten Tekuzman 

作者机构：Hacettepe University Faculty of Medicine Department of Internal Medicine Ankara Turkey Hacettepe University Institute of Ontology Ankara Turkey Hacettepe University Faculty of Medicine Department of Internal Medicine Unit of Gastroenterology Ankara Turkey 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2006年第12卷第12期

页      面：1978-1979页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：巨细胞病毒胃炎 非霍奇金淋巴瘤 病理机制 临床表现 

摘      要：Rituximab is a chimeric monoclonal antibody against CD20 antigen expressed on most B cells and is used for the treatment of malignant lymphomas expressing the CD20 antigen. It temporarily eliminates normal B-lymphocytes without a substantial decrease in serum immunoglobulin levels. Recently, several serious viral infections have been reported in association with rituximab use. Cytomegalovirus （CMV） is one of the agents that may be a cause of morbidity and mortality in immunocompromised individuals. In the face of exogenous or endogenous causes of immunosuppression, cytomegalovirus can result in retinitis, colitis, pneumonitis, or encephalitis. Presented here is a case of a patient with non-Hodgkin＇s lymphoma （NHL） who developed gastritis and enterocolitis due to CMV infection after treatment with rituximab.